Pharmaceuticals

Jincheng Pharm

Jincheng Pharm released FY2026 Q1 earnings on April 23 After-Market (BJT), actual revenue CNY 750.42 M, actual EPS CNY 0.15

Jincheng Pharm to Release FY2026 Q1 Earnings on April 24 After-Market (BJT)

Jincheng Pharm released FY2025 earnings on March 26 After-Market (BJT), actual revenue CNY 2.737 B, actual EPS CNY 0.12

Jincheng Pharm released FY2025 Q4 earnings on March 26 After-Market (BJT), actual revenue CNY 804.9 M, actual EPS CNY 0.0436

Jincheng Pharm FY2025 Annual Earnings Release on March 27, 2026 After-Market BJT

Jincheng Pharm released FY2025 9 Months Earnings on October 26 During-Market (BJT), Actual Revenue CNY 1.932 B, Actual EPS CNY 0.0809

Jincheng Pharm released FY2025 Q3 earnings on October 26 During-Market (BJT), actual revenue CNY 571.78 M, actual EPS CNY -0.0298

Jincheng Pharm FY2025 Q3 Earnings Release on October 27, 2025 During-Market (BJT)

Jincheng Pharm released FY2025 Q2 earnings on August 20 After-Market (BJT), actual revenue CNY 638.32 M, actual EPS CNY 0.0208

Jincheng Pharm released FY2025 Semi-Annual Earnings on August 20 After-Market (BJT), actual revenue CNY 1.36 B, actual EPS CNY 0.11

Jincheng Pharm to Release FY2025 Semi-Annual Earnings on August 21, 2025 (BJT)

Jincheng Tai'er Obtains Pharmaceutical Import License for Progesterone Cream from Korea

Jincheng Medicine Subsidiary Obtains European CEP Certification

Advancement of Jin Cheng Medicine's Innovative Drug R&D

Jincheng Medicine's Subsidiary's Cefodizime Sodium Injection Passes Consistency Evaluation

Jincheng Pharmaceutical Adds [Pet Economy] Concept

Jincheng Medicine's subsidiary obtains approval for additional cefmetazole sodium injection specifications

Jincheng Medicine Subsidiary Receives FDA Approval for Posaconazole API Registration

Jincheng Pharmaceutical Outlines Progress of Innovative Cancer Drug R&D

02513

002793

002589

300233

In the morning session, the CPO concept strengthened again, with DSBJ hitting the daily limit, EverProX rising over 5% to continue setting new record highs, and LINKTEL TECHNOLOGIES, Huamao Technology, TACLINK, and CIG following the gains. Innovative drug stocks were active against the trend in the morning, with YIBAI PHARMACEUTICAL achieving three daily limits in six days, Menovo hitting the daily limit, and Jincheng Pharm, JINLING PHARM., Luoxin Pharmaceutical, and Realcan following the upward trend

Wallstreetcn

KNOWLEDGE ATLAS

Luoxin Pharmaceutical

Realcan

DSBJ

EverProX

JINLING PHARM.

TACLINK

Menovo

LINKTEL TECHNOLOGIES

YIBAI PHARMACEUTICAL

GTJA Allianz CSI All Share Semiconductors & Semiconductor Equipment ETF

Tianhong CSI Computer Theme ETF

GTJA Allianz SSE STAR Chip Design Thematic ETF

ChinaAMC SSE STAR Semiconductor Material & Equipment Thematic ETF

Guotai CSI Computer Theme ETF

China Southern CSI Semiconductor Industry Custom ETF

Guotai CES Semiconductor Chip Industry ETF

ChinaAMC Guozheng Semiconductor Chip ETF

A-share Three Major Indices Fell Collectively, Computing Hardware Active Against the Trend, Hang Seng Tech Index Down Over 1%, AI Large Model Stocks Rebound, KNOWLEDGE ATLAS Rises 7%

On October 28th, Jincheng Pharm announced that its wholly-owned subsidiary Beijing Jincheng Tail Pharmaceutical Co., Ltd. and its holding subsidiary Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd. participated in the bidding for the 11th batch of national centralized drug procurement organized by the National Organization for Drug Centralized Procurement and Use Joint Procurement Office. Jincheng Tail's Rebapamide tablets and Jincheng Jinsu's injectable Cefazolin Sodium are expected to be selected in this centralized procurement

Zhitong

Jincheng Pharm: Subsidiary products are expected to be selected for the 11th batch of national centralized drug procurement

Jincheng Pharm's subsidiary, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., has obtained a drug registration certificate issued by the National Medical Products Administration. The registered product is Morpholine Nitrazole Sodium Injection. This medication is a 5-nitroimidazole antibacterial drug, suitable for various adult infections caused by sensitive bacteria, including gynecological pelvic inflammatory disease and suppurative appendicitis

Jincheng Pharm: Morphine Nitrazepam Sodium Injection has obtained a drug registration certificate

Jincheng Pharm's subsidiary Beijing Jincheng Tail Pharmaceutical Co., Ltd. has received the approval notice for the supplementary application of drugs from the National Medical Products Administration, involving changes in the types and quantities of excipients, processes, and quality standards for Progesterone cream. According to IMS data, the global sales of Progesterone formulations are projected to be USD 78.0961 million, USD 94.3352 million, and USD 104 million from 2022 to 2024, respectively. This approval will enhance product competitiveness, but will have a limited impact on current performance

Jincheng Pharm: Subsidiary receives approval notice for drug supplementary application

000661

300558

603590

688319

A-share innovative drug concept stocks fluctuated lower, with BETTA PHARMACEUTICALS falling over 10%, Jincheng Pharm, Konruns, Baillie Tianheng, Olymvax Biopharmaceuticals, and CCHT all dropping more than 5%

CCHT

BETTA PHARMACEUTICALS

Konruns

Olymvax Biopharmaceuticals

Jincheng Pharm announced that its actual controller Zhao Yeqing received the "Notice of Administrative Penalty" from the China Securities Regulatory Commission, due to suspected manipulation of the securities market. Zhao Yeqing, Wang Zhen, and Liu Feng will each be fined 3 million yuan, with Zhao Yeqing bearing 1.5 million yuan and facing a 4-year market ban, while Wang Zhen faces a 3-year ban. Zhao Yeqing will apply for a hearing in accordance with the law

The actual controller of Jincheng Pharm received a notice of administrative penalty in advance

Jincheng Pharm announced that its wholly-owned subsidiary Beijing Jincheng Tail Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the marketing application of Clobetasol Propionate chemical raw material. Clobetasol Propionate is a PDE-4 inhibitor indicated for the topical treatment of mild to moderate atopic dermatitis in patients aged 3 months and older. According to IMS data, the global sales of Clobetasol Propionate formulations are projected to be USD 224 million, USD 206 million, and USD 196 million from 2022 to 2024, with the consumption of raw materials increasing year by year

Jincheng Pharm: Klibor has obtained approval for the listing application of chemical raw materials

According to the Zhitong Finance APP, Jincheng Pharm announced that its wholly-owned subsidiary Beijing Jincheng Tail Pharmaceutical Co., Ltd. recently received the "Approval Notice for the Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration. The name of the chemical raw material is: Mirabegron. Mirabegron is a selective β-3 adrenergic receptor agonist, primarily used for the treatment of overactive bladder (OAB), including symptoms such as urinary incontinence, urgency, and frequency

Jincheng Pharm: Mirabegron has obtained approval for the listing application of chemical raw materials

On August 25th, Jincheng Pharm stated on the interactive platform that the company is collaborating with Heze Pharmaceuticals on project cooperation in the field of women's health, with products primarily focused on hormone supplementation for perimenopausal and menopausal women

Jincheng Pharm: The company is collaborating with Heze Pharma on project cooperation in the field of women's health

Jincheng Pharm released its semi-annual report for 2025, reporting an operating income of 1.36 billion yuan, a year-on-year decrease of 22.65%; net profit attributable to shareholders was 43.3832 million yuan, a year-on-year decrease of 66.78%; net profit excluding non-recurring gains and losses was 38.7305 million yuan, a year-on-year decrease of 68.12%; basic earnings per share were 0.11 yuan

Jincheng Pharm released its performance for the first half of the year, with a net profit attributable to the parent company of 43.3832 million yuan, a year-on-year decrease of 66.78%

Jincheng Pharm(300233.SZ)